Adagene Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ADAG | MGNX | CGEN | PYXS | CHRS | ANL | |
|---|---|---|---|---|---|---|
| Market cap | 161.82M | 147.15M | 192.29M | 198.30M | 131.36M | 618.86M |
| P/E (TTM) | — | — | 5.3 | — | — | — |
| Forward P/E | -4.3 | -1.6 | -5.5 | -1.5 | -1.3 | -32.7 |
| Price/book | 1.8 | 3.4 | 2.2 | 9.2 | 2.2 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +49.69% | +61.81% | +23.78% | −58.91% | −42.95% | +520.00% |
| Today | +2.55% | −0.86% | +1.00% | +1.22% | +5.54% | +0.31% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ADAG news ›AC Immune Third Quarter 2026 Financial and Corporate Update
Gary Waanders, Ph.D., MBA Phone: +41 21 345 91 91 Nick Bastin, Joshua Evans, Aoife Minihan, Ben Cowe Phone: +44 (0) 20 4566 8543 AC Immune (NASDAQ: ACIU) is a clinical-stage biopharma company selectively targeting the key pathologic misfold
ACG Acquisition’s (ACG) Buy Rating Reiterated at Berenberg Bank
Posted by Mitch Edgeman on Nov 3rd, 2026 ACG Acquisition (LON:ACG – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Berenberg Bank in a research note issued on Tuesday, Digital Look reports. They presently have a…
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology…
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology comp... Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference…
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyteâs INCA33890 in Patients with Microsatellite Stable Colorectal Cancer Adagene Announces Dosing of First Patient in Phase 1 Study of…
Adyen (ADYYF) Gets a Buy from Jefferies
In a report released today, Hannes Leitner from Jefferies maintained a Buy rating on Adyen, with a price target of €1,233.00. According to TipRanks, Leitner is a 4-star analyst with an average return of 9.5% and a 54.55% success rate.…
Adagene’s (ADAG) Buy Rating Reiterated at HC Wainwright
Adagene (NASDAQ:ADAG – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Monday, MarketBeat.com reports. They presently have a $7.00 target price on the stock. HC Wainwright’s price…
HC Wainwright & Co. reiterates Buy rating on Americas Gold And Silver, $9.25 price target
HC Wainwright & Co. reiterated their Buy rating on Americas Gold And Silver's stock with a price target of $9.25. The price target implies an upside of 145.4% from the Oct 19 close of $3.77. Strong Production Performance: Americas Gold And…
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Posted by Mitch Edgeman on Oct 16th, 2026 Adagene (NASDAQ:ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company’s antibody pipeline, its approach to masked therapies and upcoming development…
From the 4Search news index, newest first.
In the news
People in the coverage
Most coverage from
- markets.businessinsider.com5
- defenseworld.net4
- themarketsdaily.com2
- bethesdamagazine.com1
- businessupturn.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.